| [1] |
黄健，王建业，孔垂泽, 等. 2019版中国泌尿外科疾病诊断治疗指南[M]. 北京: 人民卫生出版社, 2020, 51-52.
|
| [2] |
Vashistha V, Wang HZ, Mazzone A, et al. Radical cystectomy compared to combined modality treatment for muscle-invasive bladder cancer: a systematic review and meta-analysis[J]. 2017, 97(5): 1002-1020.
|
| [3] |
Jason AE, Daphna YS, William US, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the mgh experience[J]. Eur Urol, 2012, 61(4): 705-711.
URL
|
| [4] |
Hamad J, McCloskey H, Milowsky MI, et al. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review[J]. Int Braz J Urol, 2020, 46(2): 169-184.
|
| [5] |
吴肇汉，秦新裕，丁强, 等. 实用外科学[M]. 北京: 人民卫生出版社, 2017, 1896-1897.
|
| [6] |
Kim YJ, Byun SJ, Ahn H, et al. Comparison of outcomes between trimodal therapy and radical cystectomy in muscle-invasive bladder cancer: a propensity score matching analysis[J]. Oncotarget, 2017, 8(40): 68996-69004.
|
| [7] |
Rödel C, Grabenbauer GG, Kühn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results[J]. J Clin Oncol, 2002, 20(14): 3061-3071.
|
| [8] |
Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome[J]. J Clin Oncol, 2001, 19(1): 89-93.
|
| [9] |
Zhuo L, Fan Q, Lin Q, et al. VEGF-C as a decision-making biomarker for selected patients with invasive bladder cancer who underwent bladder-preserving radical surgery[J]. Arch Med Res, 2011, 42(5): 405-411.
URL
|
| [10] |
Hamad J, McCloskey H, Milowsky MI, et al. Bladder preservation in muscle-invasive bladder cancer: a comprehensive review[J]. Int Braz J Urol, 2020, 46(2): 169-184.
|
| [11] |
Krause FS, Walter B, Ott OJ, et al. 15-year survival rates after transurethral resection and radiochemotherapy or radiation in bladder cancer treatment[J]. Anticancer Res, 2011, 31(3): 985-990.
URL
|
| [12] |
Toshiki Kijima, Hajime Tanaka, Sho Uehara, et al. Clinical outcomes of patients with histologic variants of urothelial carcinoma treated with selective tetramodal bladder-preservation therapy incorporating consolidative partial cystectomy[J]. Clin Genitourin Cancer, 2020, 18(4): 268-273.e2.
|
| [13] |
Marko B, Maximilian B, Eva MC, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update[J]. Eur Urol, 2019, 76(5): 639-657.
|
| [14] |
Rauf TD, Ümi̇t Y, Ferruh Z, et al. The Effect of Repeat Transurethral Resection on Recurrence and Progression Rates in Patients With T1 Tumors of the Bladder Who Received Intravesical Mitomycin: A Prospective, Randomized Clinical Trial[J]. J Urol, 2006, 175(5): 1641-1644.
|
| [15] |
Wojciech K, Łukasz N, Sławomir P, et al. The impact of restaging transurethral resection of bladder tumor on survival parameters in t1 nonmuscle-invasive bladder cancer: systematic review and meta-analysis[J]. J Endourol, 2020, 34(8): 795-804.
|
| [16] |
Paramananthan M, Alexandra Z, Kenneth MG，et al. Detrusor muscle in the first, apparently complete transurethral resection of bladder tumour specimen is a surrogate marker of resection quality, predicts risk of early recurrence, and is dependent on operator experience[J]. Eur Urol, 2010, 57(5): 843-849.
URL
|
| [17] |
Evren S, Nurullah H, Mehmet IG, et al. Significance of second transurethral resection on patient outcomes in muscle-invasive bladder cancer patients treated with bladder-preserving multimodal therapy[J]. World J Urol, 2016, 34(6): 847-851.
|
| [18] |
周先明，疏仁义，郭荣利, 等.T2a期膀胱尿路上皮癌行二次电切治疗的应用价值[J/CD]. 中华腔镜泌尿外科杂志(电子版), 2019, 13(2): 125-127.
|
| [19] |
杨诚，陈伟，梁朝朝.非肌层浸润性膀胱癌行二次电切术的临床意义及相关危险因素分析[J]. 中华泌尿外科杂志, 2019, 40(7): 498-502.
|
| [20] |
Kimberley SM, Angela BS, Alec E, et al. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer[J]. Int J Radiat Oncol Biol Phys, 2016, 96(5): 1028-1036.
|
| [21] |
Spiess PE, Agarwal N, Bangs R, et al. Bladder Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2017, 15(10): 1240-1267.
|